# EDGAR Filing Document

**Accession Number:** 0000897448
**File Stem:** 0001140361-23-007713
**Filing Date:** 2023-2
**Character Count:** 9193
**Document Hash:** 858e05521808f51392f74cb43500b524
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-007713.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001140361-23-007713

**CONFORMED SUBMISSION TYPE**: DFAN14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21392
- **FILM NUMBER:** 23645095

**BUSINESS ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sarissa Capital Management LP
- **CENTRAL INDEX KEY:** 0001577524
- **IRS NUMBER:** 900924432
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DFAN14A

**BUSINESS ADDRESS:**
- **STREET 1:** 660 STEAMBOAT ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** 203-302-2330

**MAIL ADDRESS:**
- **STREET 1:** 660 STEAMBOAT ROAD
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830

------

#### UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION <br> Washington, D.C. 20549

#### <br>

### SCHEDULE 14A

#### <br>
**Proxy Statement Pursuant to Section 14(a) of the<br> Securities Exchange Act of 1934**<br>

Filed by the Registrant ☐

Filed by a party other than the Registrant ☒

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material under § 240.14a-12

#### Amarin Corporation plc
(Name of Registrant as Specified In Its Charter)

#### Sarissa Capital Catapult Fund LLC

#### Sarissa Capital Hawkeye Fund LP

#### ISP Fund LP

#### Sarissa Capital Offshore Master Fund LP

#### Sarissa Capital Master Fund II LP

#### Sarissa Capital Athena Fund Ltd

#### Atom Master Fund LP

#### Sarissa Capital Fund GP LP

#### Sarissa Capital Fund GP LLC

#### Sarissa Capital Offshore Fund GP LLC

#### Sarissa Capital Management GP LLC

#### Sarissa Capital Management LP

#### Alexander J. Denner, Ph.D.

#### Patrice Bonfiglio

#### Paul Cohen, M.D.<br> Mark DiPaolo<br> Keith L. Horn<br> Odysseas Kostas, M.D.

#### Louis Sterling III<br> Diane E. Sullivan
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

This filing contains a press release issued on February 20, 2023 by Sarissa Capital.

------

#### SARISSA CAPITAL URGES AMARIN SHAREHOLDERS TO VOTE

#### "FOR" NECESSARY CHANGE

#### Sarissa believes Amarin leadership will continue to destroy shareholder value during this

#### critical period; We cannot afford to maintain the status quo

#### Sarissa has a stellar track record of success and its nominees have the experience and

#### qualifications to help fix the problems at Amarin

Greenwich, CT, February 20, 2023 – Sarissa Capital Management LP ("Sarissa") today issued the following statement regarding Amarin Corporation plc (NASDAQ: AMRN):

Sarissa urges Amarin shareholders to vote "FOR" necessary change at our upcoming shareholder meeting. The outcome of this meeting will significantly affect the future of Amarin. The decision is one of maintaining the status quo with the current regime which has overseen a tremendous destruction of shareholder value or remaking Amarin for the benefit of shareholders.

Amarin has a uniquely valuable drug Vascepa/Vazkepa that can meaningfully reduce cardiovascular events in patients and save significant resources for health systems worldwide. This highly beneficial and rare profile of Vascepa/Vazkepa has been significantly underutilized by the current regime. Amarin is at a critical juncture where strategic decisions must be made by a board that seeks to leverage the strengths of the company's assets for the benefit of shareholders. Unfortunately, the current leadership has a history of operational blunders and poor capital allocation decisions. Even more disappointing, the current regime repeatedly attempts to obfuscate the truth with many misstatements about their performance and Sarissa's stellar track record of success in order to secure votes.

Sarissa did not engage in this proxy contest lightly. We were compelled to do so after witnessing egregious corporate governance and experiencing the painful collapse of the share price, like other shareholders. As Amarin's largest shareholder with a history of value creation in the cardiovascular space, Sarissa believes it can help fix the company's problems and unlock the true potential of Amarin with its nominees on the board. We have a stellar track record of success with the average performance of our portfolio companies during the tenure of Sarissa and Sarissa designees being +39.7%.\* In contrast, Amarin's performance under CEO Karim Mikhail and Chairman Per Wold-Olsen were -70.8% and -62.8% respectively.<sup>†</sup> We believe current Amarin leadership should be accountable to shareholders, the owners of the company, for their poor performance.

We cannot afford to allow the current regime to destroy further shareholder value. Our slate includes Sarissa candidates that helped turn around The Medicines Company until its ultimate sale for nearly $10 billion. We have the qualifications and the experience to help guide Amarin through this critical period.

Please see our latest presentation published February 17, 2023: <u>https://freeamarin.com/wp-content/pdfs/vote-for-change.pdf</u>

------

We urge all shareholders to vote "**FOR**" the Sarissa Nominees and "**FOR**" the removal of Chairman Per Wold-Olsen on or prior to the deadline on Tuesday, February 21, 2023.

You can vote on the blue proxy card or the white proxy card but if you want to fully support Sarissa, you must make sure that all "**FOR**" boxes are marked on your proxy card (blue or white) before you submit it.

If you have any questions on how to vote, we recommend that you contact Sarissa's proxy solicitor, D.F. King, by calling (800) 331-7024 or emailing <u>AMRN@dfking.com</u>.

Visit our website at <u>www.freeamarin.com</u><u> </u>for helpful information about Sarissa and the need for change at Amarin.

**IF YOU ALREADY VOTED "FOR" ALL PROPOSALS AND SUBMITTED YOUR BLUE PROXY CARD, THERE IS NOTHING ELSE YOU NEED TO DO TO SUPPORT SARISSA'S NOMINEES. YOU DO NOT NEED TO VOTE AGAIN.**

The General Meeting of Amarin shareholders is scheduled for February 28, 2023, BUT TO MAKE SURE YOUR VOTE COUNTS, **<u>SUBMIT YOUR VOTE ON OR BEFORE TUESDAY, FEBRUARY 21, 2023</u>**.

\* Calculated as average price change where a Sarissa or Sarissa-affiliated director held tenure as a board member, for larger Sarissa portfolio positions defined as (≥$50M), between the date immediately preceding their first date-in service and 12/30/2022. Not weighted by investment and not indicative of Sarissa's investment returns.

† Calculated as price change between the dates 7/30/2021 and 12/30/2022 for CEO Karim Mikhail and 1/7/2022 and 12/30/2022 for Per Wold-Olsen.

#### Additional Information

Sarissa Capital Management LP ("Sarissa Capital"), together with other participants, filed a definitive proxy statement and an accompanying blue proxy card with the SEC on January 31, 2023, in connection with the solicitation of shareholders of Amarin Corporation plc (the "Company") at the general meeting of the Company for the election of Sarissa Capital's slate of highly-qualified nominees (the "General Meeting"). Shareholders are advised to read the definitive proxy statement and other relevant documents related to the General Meeting as they contain important information.

The definitive proxy statement and other relevant documents are available at no charge on the SEC's website at <u>www.sec.gov</u> and at <u>www.freeamarin.com</u>. The definitive proxy statement and other relevant documents are also available at no charge by directing a request to Sarissa Capital's proxy solicitor, D.F. King & Co., Inc., 48 Wall Street, New York, New York 10005 (Shareholders can call toll-free: (800) 331-7024).

#FreeAmarin

Contact: Jean Puong<br> Sarissa Capital Management LP<br> <u>info@sarissacap.com</u>

------

<br>